Rate My Professor Russell Scott

Professor Scott has made substantial contributions to the field through participation in major clinical trials and publications. Notable works include Raal FJ et al. (2015), 'PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia', published in The Lancet; Redondo MJ et al. (2018), 'A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk', in Diabetes Care; Scott R et al. (2018), 'A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study', in Diabetes, Obesity & Metabolism; Willis J et al. (2022), 'Type 1 diabetes diagnosed before age 15 years in Canterbury, New Zealand: A fifty year record of increasing incidence', in Pediatric Diabetes; and Watts GF et al. (2023), on RNA interference for triglyceride lowering. He delivered the plenary presentation 'What's hot in diabetes?' at the South General Practice Conference & Medical Exhibition in Christchurch in 2020. His work advances understanding and management of metabolic disorders with significant clinical impact.